Brain bleed dilemma: statins – friend or foe?

NCT ID NCT03936361

Recruiting now Disease control Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial is testing whether people who have a brain hemorrhage (bleeding stroke) should continue or stop taking their statin medication. The study will follow 1,456 participants for years to see which strategy leads to fewer repeat bleeds or other serious events. It also looks at whether a person's genes (APOE) affect the best choice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Statins (cholesterol-lowering drugs)
What this could lead to: If it works, this could guide doctors on whether to continue or stop statins after a brain hemorrhage, potentially reducing the risk of another bleed or stroke.
What could go wrong: This is a large trial, but results may not apply to all patients. Statins have known side effects like muscle pain, and stopping them could increase heart risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRACEREBRAL HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRACEREBRAL HEMORRHAGE

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.